2-piperidone has been researched along with cc-122 in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 9 (69.23) | 2.80 |
| Authors | Studies |
|---|---|
| Czarnik, AW; DeWitt, SH; Jacques, V; Judge, TM; Van der Ploeg, LH | 1 |
| Amantangelo, MD; Barnes, L; Bjorklund, C; Breider, M; Cai, T; Chiu, H; Chopra, R; Couto, S; Daniel, TO; Fontanillo, C; Gandhi, AK; Hagner, PR; Havens, CG; Kang, J; Khambatta, G; Klippel, A; Kosek, J; Lopez-Girona, A; Lu, G; Man, HW; Narla, RK; Pourdehnad, M; Raymon, H; Rychak, E; Schafer, PH; Thakurta, A; Trotter, M; Waldman, M; Wang, M | 1 |
| Chopra, R; DiMartino, J; Gandhi, AK; Hagner, PR; Hege, K; Li, Y; Papadopoulos, KP; Pourdehnad, M; Rasco, DW; Shih, K; Wei, X | 1 |
| Carayannopoulos, LN; Chen, J; Li, Y; Liu, L; MacGorman, K; Ogasawara, K; Palmisano, M; Zhou, S | 1 |
| Chen, J; Hoffmann, M; Li, Y; Liu, L; MacGorman, K; Palmisano, M; Zhou, S | 1 |
| Bouabdallah, R; Buchholz, TJ; Carpio, C; Carrancio, S; Cordoba, R; Couto, S; Damian, S; Gandhi, AK; Gharibo, M; Hagner, PR; Hege, K; Lopez-Martin, JA; Martin, A; Panizo, C; Pinto, A; Pourdehnad, M; Rasco, D; Ribrag, V; Risueño, A; Salar, A; Salles, G; Sancho, JM; Santoro, A; Schmitz, F; Trotter, MWB; Van den Neste, E; Verhoef, G; Wang, M; Wang, X; Wei, X; Weng, A; Ysebaert, L | 1 |
| Bijou, F; Bouabdallah, R; Chen, T; Chiappella, A; Doorduijn, JK; Hagner, PR; Hege, K; Kersten, MJ; Klein, C; Mendez, C; Michot, JM; Mosulen, S; Nikolova, Z; Pourdehnad, M; Ribrag, V; Salles, G; Sarmiento, R; Uttamsingh, S; Vitolo, U; Zinzani, PL | 1 |
| Luminari, S | 1 |
| Amini, RM; Apollonio, B; Awan, FT; Chiu, H; Fanous, M; Gandhi, AK; Hagner, PR; Ioannou, N; Janardhanan, P; Jones, J; Kay, NE; Lopez-Girona, A; Papazoglou, D; Patten, PEM; Ramsay, AG; Rosenquist, R; Shanafelt, TD; Stamatopoulos, K; Stokes, M; Sutton, LA; Tallman, MS; Vardi, A | 1 |
| Chou, T; Doi, T; Fujimoto, H; Hagner, PR; Hatake, K; Hirose, T; Kato, H; Ogaki, Y; Pourdehnad, M; Seo, S; Terui, Y; Yamamoto, K | 1 |
| Baughman, JM; Fontanillo, C; Jang, IS; Khater, M; Lu, G; Mizukoshi, R; Mo, Z; Namiranian, S; Rolfe, M; Silva-Torres, A; Slade, M; Wang, K; Weng, S; Wood, S | 1 |
| Abbiati, RA; Carrancio, S; Kasibhatla, S; Loos, R; McConnell, M; Pierce, DW; Pourdehnad, M; Ratushny, AV; Santini, CC; Trotter, MWB | 1 |
| Hartmann, MD; Heim, C | 1 |
5 trial(s) available for 2-piperidone and cc-122
| Article | Year |
|---|---|
CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; B-Lymphocytes; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Ikaros Transcription Factor; Interferon Regulatory Factor-7; Interferons; Lenalidomide; Lentivirus; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, SCID; Molecular Mimicry; Peptide Hydrolases; Piperidones; Proteolysis; Quinazolinones; RNA, Small Interfering; Signal Transduction; T-Lymphocytes; Thalidomide; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2015 |
A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Piperidones; Quinazolinones; Ubiquitin-Protein Ligases | 2019 |
Single-Dose Pharmacokinetics, Safety, and Tolerability of Avadomide (CC-122) in Subjects With Mild, Moderate, or Severe Renal Impairment.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Carcinoma, Hepatocellular; Case-Control Studies; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Female; Genetic Pleiotropy; Glioblastoma; Hematologic Neoplasms; Humans; Liver Neoplasms; Male; Middle Aged; Piperidones; Quinazolinones; Renal Insufficiency; Safety; Severity of Illness Index; Ubiquitin-Protein Ligases | 2020 |
Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Half-Life; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neutropenia; Piperidones; Quinazolinones; Recurrence; Severity of Illness Index; Thrombocytopenia; Treatment Outcome | 2020 |
Phase I, multicenter, dose-escalation study of avadomide in adult Japanese patients with advanced malignancies.
Topics: Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Humans; Japan; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Piperidones; Quinazolinones | 2021 |
8 other study(ies) available for 2-piperidone and cc-122
| Article | Year |
|---|---|
Differentiation of antiinflammatory and antitumorigenic properties of stabilized enantiomers of thalidomide analogs.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Female; Humans; Inflammation; Leukocytes, Mononuclear; Mice; Mice, SCID; Models, Chemical; Neoplasm Transplantation; Neoplasms; Piperidones; Quinazolinones; Stereoisomerism; Thalidomide; Tumor Necrosis Factor-alpha | 2015 |
Drug-Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC-122) in Healthy Adult Subjects.
Topics: Adult; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Healthy Volunteers; Humans; Male; Middle Aged; Piperidones; Quinazolinones; Rifampin; Young Adult | 2019 |
Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Drug Resistance, Neoplasm; Female; Humans; Immunophenotyping; Lymphoma, Large B-Cell, Diffuse; Macrophages; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Piperidones; Prognosis; Quinazolinones; Recurrence; Retreatment; T-Lymphocytes; Treatment Outcome | 2020 |
New IMiD on the block.
Topics: Antibodies, Monoclonal, Humanized; B-Lymphocytes; Humans; Lymphoma, Non-Hodgkin; Piperidones; Quinazolinones | 2020 |
Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy.
Topics: Animals; Antineoplastic Agents; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Interferons; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Activation; Mice; Piperidones; Quinazolinones; Signal Transduction; T-Lymphocytes; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2021 |
Deciphering the mechanisms of CC-122 resistance in DLBCL via a genome-wide CRISPR screen.
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Clustered Regularly Interspaced Short Palindromic Repeats; Humans; Lymphoma, Large B-Cell, Diffuse; Piperidones; Potassium Channels; Quinazolinones; Ubiquitin-Protein Ligases | 2021 |
Quantitative Systems Pharmacology Modeling of Avadomide-Induced Neutropenia Enables Virtual Clinical Dose and Schedule Finding Studies.
Topics: Antineoplastic Agents; Biological Variation, Population; Computer Simulation; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Models, Biological; Network Pharmacology; Neutropenia; Neutrophils; Piperidones; Quinazolinones | 2021 |
High-resolution structures of the bound effectors avadomide (CC-122) and iberdomide (CC-220) highlight advantages and limitations of the MsCI4 soaking system.
Topics: Morpholines; Phthalimides; Piperidones; Quinazolinones | 2022 |